US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc (NYSE: GSK, LON: GSK) to discover and develop innovative treatments for Parkinson’s disease (PD) and another undisclosed neurodegenerative condition. The alliance leverages Vesalius’ platform to identify novel intervention points in PD and an additional neurodegenerative indication, providing GSK with the option to advance these programs.
Global Rights and Development Focus
GSK will acquire worldwide development and commercial rights from Vesalius to a preclinical small molecule program initially focused on PD. GSK will be responsible for advancing Vesalius’ preclinical small molecule program and has the option to progress programs for novel intervention points identified in PD and another neurodegenerative indication.
Financial Commitment and Milestone Payments
Under the agreement, GSK will make upfront and equity payments totaling USD 80 million and is committed to potential preclinical, development, and commercial milestone payments of up to USD 570 million, along with tiered royalties for the preclinical small molecule program. Additionally, Vesalius is eligible to receive milestone payments and tiered royalties for each novel intervention point resulting from the multi-target deal, with the potential total payment for each point remaining undisclosed.-Fineline Info & Tech
Leave a Reply